MM+M Women of Distinction honoree, announced Monday morning that she has joined Medtronic Diabetes as its chief marketing ...

On the FDA’s docket this month are two expansion bids, one for GSK’s asthma drug Nucala into COPD and another for Merck’s ...

Researchers aim to develop a universal vaccine platform that could protect against both COVID-19 and influenza without annual ...

The FDA is expected to unpause the only protein-based COVID-19 vaccine's transition from emergency approval to full approval.

Have you ever wondered about what became of COVID vaccine companies after the pandemic settled down? Find out in this article ...

If the FDA deems Pfizer’s and Moderna’s updated vaccines “new” products, it’s extremely unlikely the doses would be ready for ...

The US Department of Health and Human Services said Thursday that it aims to accomplish within four years a scientific feat ...

Additional data required by the FDA are the latest evidence of what one analyst described as a “higher bar” for vaccines.

The plans amount to an extraordinary flex of Robert F. Kennedy Jr.’s power as health secretary to make decisions ordinarily ...

The Cambridge-based biotech company has been trying to reduce operating expenses as it burns cash on its large pipeline.

Moderna faces revenue declines, regulatory setbacks, and market challenges as COVID-19 vaccine demand wanes. Learn more about ...

Moderna reports Q1 2025 results with $108M revenue, significant cost reductions, and advancements in vaccines & oncology.